Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
January 22 2019 - 4:30PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that
Christina Willwerth has been named Chief Strategy Officer. Ms.
Willwerth joined Flexion in June 2009, and she most recently served
as the company’s Senior Vice President of Program Management and
Strategy. In her expanded role, Ms. Willwerth will continue to lead
the planning and execution of the company’s strategic vision and
priorities, and she has accountability for Flexion’s portfolio
development efforts and Human Resources activities.
“During her tenure, Christina has served as a trusted advisor to
our entire executive team, and she has played an integral role in
shaping Flexion’s corporate priorities and advancing the
development of our portfolio,” said Michael Clayman, M.D.,
President and Chief Executive Officer. “With her collaborative
leadership style, strategic vision, and dedication to our mission,
I am confident that Christina will continue to factor centrally in
our future success in this important new role.”
Ms. Willwerth has 25 years of experience in pharmaceutical
development. Prior to joining Flexion, she served as Vice
President, Product Development at Viacell and was a member of the
company’s executive management team. Previously she served as
Senior Director, Product Development at The Medicines Company,
where she focused on clinical and product development for
cardiovascular therapies. Ms. Willwerth earned a Bachelor of
Science degree in Biology, with high distinction, from Worcester
Polytechnic Institute.
About Flexion TherapeuticsFlexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. For the past two years, Flexion has
been named one of the Best Places to Work by the Boston
Business Journal, and a Top Place to Work
in Massachusetts by The Boston Globe.
Forward-Looking Statements This release
contains forward-looking statements that are based on the current
expectations and beliefs of Flexion. Statements in this
release regarding matters that are not historical facts, including,
but not limited to, statements relating to the future expected
benefits of Flexion's appointment of Ms. Willwerth to Chief
Strategy Officer, are forward-looking statements. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this release and are subject to
numerous risks and uncertainties which could cause actual results
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include, without
limitation, whether we are able to retain key employees including
Ms. Willwerth; our ability to meet our goals; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission (SEC), including under the heading "Risk
Factors" in our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018 filed with the SEC on November 7, 2018 and
subsequent filings with the SEC. The forward-looking
statements in this release speak only as the date of this release,
and we undertake no obligation to update or revise any of the
statements. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
Contacts:
Scott Young Vice President, Corporate Communications &
Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194
syoung@flexiontherapeutics.com
Julie Downs Manager, Corporate Communications Flexion
Therapeutics, Inc. T: 781-305-7137
jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2024 to May 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From May 2023 to May 2024